Oragenics Inc.

Item 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT Effective July 1, 2026, the Board of Directors (the “Board”) of Oragenics, Inc. (the “Company”) appointed John Spencer, the Company’s Senior Controller, to serve as the Company’s Chief Financial Officer, and, in connection therewith, effective July 1, 2026, the Company entered into an Executive Employment Agreement with Mr. Spencer (the “Employment Agreement”). The Employment Agreement provides for base compensation of $200,000. The Employment Agreement contains customary confidentiality, non-competition and non-solicitation provisions. The foregoing summary is qualified in its entirety by the specific terms of the Employment Agreement attached as Exhibit 10.1 to this Form 8-K which is incorporated herein by reference.

Item DEPARTURE 5.02 OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. ( e) Compensatory Arrangements of Certain Officers. Effective July 1, 2026, the Board appointed John Spencer, the Company’s Senior Controller, to serve as the Company’s Chief Financial Officer. In connection with the appointment of Mr. Spencer as the Company’s Chief Financial Officer, Mr. Spencer received an option award equal to $25,000, with an exercise price equal to the closing price of the Company’s common stock on the NYSE American immediately prior to the date of the grant. Mr. Spencer, age 32, joined the Company in April 2025 as Senior Controller and has led the Company’s finance and accounting organization, including SEC reporting, financial planning and analysis, treasury, budgeting, internal controls, audit coordination, and capital markets support. From March 2022 through April 2025, Mr. Spencer operated a fractional chief financial officer and financial consulting practice, providing financial leadership to publicly traded and privately held companies across multiple industries, including healthcare, sports and entertainment, and professional services. His responsibilities included SEC reporting, financial planning and analysis, budgeting and forecasting, treasury, internal controls, acquisition accounting, capital planning, operational finance, and strategic financial leadership. Previously, Mr. Spencer served as Vice President of Finance at Trxade Health, Inc., a publicly traded healthcare technology company, where he was responsible for SEC reporting, financial planning and analysis, internal controls, acquisition accounting, finance operations, and strategic finance initiatives. Mr. Spencer began his career with PricewaterhouseCoopers LLP, where he provided audit and tax services to publicly traded and privately held companies. Mr. Spencer is a Certified Public Accountant in the State of Florida and received both a Master of Accountancy and a Bachelor of Science in Accounting from the University of South Florida. There are no arrangements or understandings between Mr. Spencer and any persons pursuant to which Mr. Spencer would be selected as an officer. There are no current or proposed transactions between the Company and Mr. Spencer or his immediate family members that would require disclosure under item 404(a) of Regulations S-K promulgated by the Securities and Exchange Commission.

Item SUBMISSION 5.07 OF MATTERS TO A VOTE OF SECURITY HOLDERS. (a) The Annual Meeting was held on June 29, 2026. (b) At the Annual Meeting the following proposals were voted on by our shareholders: PROPOSAL 1: Election of Directors. Mr. Charles Pope, Dr. Frederick Telling, Mr. Robert Koski, Dr. Alan Dunton, Mr. John Gandolfo and Ms. Natasha Giordano were each re-elected as Directors, to serve until our next annual meeting of shareholders or until their respective successors are elected and qualified or until their earlier resignation, removal from office or death. The votes were as follows: For Withheld Broker Non-Votes ───────────────────────────────────────────────────────────────── Charles 1,017,697 292,270 793,522 Pope Dr. 1,018,895 291,072 793,522 Frederick Telling Dr. 1,016,221 293,746 793,522 Alan Dunton Robert 1,018,560 291,407 793,522 Koski John 1,014,185 295,782 793,522 Gandolfo Natasha 984,704 325,263 793,522 Giordano PROPOSAL 2: To conduct a non-binding advisory vote on executive compensation. The votes were as follows: FOR 806,898 AGAINST 478,522 ABSTAIN 24,545 BROKER 793,522 NON-VOTES PROPOSAL 3: To authorize the Board of Directors to enact a reverse stock split, in its sole discretion at any time within one year after shareholder approval is obtained, to effect a reverse stock split of then-outstanding shares of the Company’s Common Stock, at a ratio of not less than one-for-two (1:2) and not greater than one-for-fifty (1:50). The votes were as follows: FOR 1,239,961 AGAINST 836,159 ABSTAIN 27,366 PROPOSAL 4: Ratification of the selection of Cherry Bekaert LLP as the Company’s independent auditors for the year ending December 31, 2026. The votes were as follows: FOR 1,887,381 AGAINST 184,883 ABSTAIN 31,225 Item 9.01. FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits Exhibit Description No. ───────────────────────────────────────────────────────────────────────────────────────────────── 10.1 Executive Employment Agreement with John Spencer. 104 Cover page Interactive Data File (embedded in the cover page formatted in Inline XBRL)